Isoniazid resistance is not a rare edge case. Isoniazid-resistant TB represents a substantial global burden, and the standard first-line regimen, HRZE, is built around isoniazid., and the standard first-line regimen, HRZE, is built around isoniazid. BioVersys and GSK now have 14-day Phase 2a data suggesting their AlpE combination could slot into that regimen where isoniazid sits, and the bactericidal activity numbers are close enough to standard-of-care to keep the program moving.
The ENABLE study (NCT06748937) tested alpibectir at 45 mg, a higher dose than used in earlier trials, paired with 125 mg or 250 mg of ethionamide, both alone and combined with rifampicin, pyrazinamide, and ethambutol (RZE). Every regimen showed bactericidal activity. The 250 mg ethionamide arm outperformed the 125 mg arm, confirming a dose-response relationship. Crucially, the AlpE 45 mg/250 mg-RZE combination produced early bactericidal activity numerically similar to the HRZE standard of care, though the trial was not powered for a formal head-to-head comparison. AlpE’s design intent is to potentiate ethionamide’s activity so that lower doses can be used effectively, which matters because ethionamide’s gastrointestinal toxicity is severe enough that ethionamide’s gastrointestinal toxicity is severe enough that many patients struggle to tolerate a full dose.
The tolerability picture from ENABLE was acceptable over the 14-day window, though that short horizon limits what can be concluded about longer-term safety. The more consequential test comes from STEP2C, a Phase 2b trial (NCT05807399) that enrolled its first patient in March 2026 and is now running AlpE-RZE through the first two months of treatment across six African countries. That duration is long enough to surface gastrointestinal signals and other tolerability concerns that a two-week study would miss. A separate Phase 2 program in TB meningitis is also active, run by BioVersys independently.
The practical question ENABLE answers is narrow but necessary: at 45 mg alpibectir with 250 mg ethionamide, the combination is active enough against drug-sensitive TB to justify testing in a longer regimen. STEP2C’s two-month tolerability and efficacy data will determine whether AlpE can actually replace isoniazid in a substantial global burden of isoniazid-resistant TB. Watch that readout.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.

